ArticlePLOS global public health2026
Enteric dysfunction and enteropathogens among hospitalized south Asian and sub-Saharan African children.
Article in PLOS global public health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Enteropathogens and enteric dysfunction (ED) among acutely ill children in low-and-middle income countries (LMICs) may contribute to poor post-discharge outcomes. Enteropathogen prevalence and fecal ED biomarkers (myeloperoxidase, calprotectin, α-1-antitrypsin) from children aged 2-23 months hospitalized at nine LMIC facilities (n = 811) were compared to community children (n = 248). Host and pathogen correlates of ED biomarkers were identified through crude and adjusted linear mixed effect models, and Cox-proportional hazard models assessed ED biomarker associations with mortality in the 30-days following admission and 180-days following discharge. Invasive enteropathogens were more prevalent at admission (69%) than discharge (60%, p < 0.001) or among community children (61%, p = 0.004). Among the biomarkers, myeloperoxidase was higher at admission (2290 ng/ml, interquartile range [IQR]: 868, 6052, p = 0.014), and lower at discharge (1380 ng/ml, IQR: 611, 3193, p < 0.001) compared to community children (2268 ng/ml, IQR: 1051, 5421), while calprotectin was similar at admission (215 ug/ml, IQR: 77, 746, p = 0.351), but lower at discharge (170 ug/ml, IQR: 68, 369, p = 0.007) when compared the community children (252 ug/ml, IQR: 124, 691). α-1-antitrypsin concentrations were lower at admission (121 mg/l, IQR: 49, 303, p = 0.049) compared to the community (201 mg/ml, IQR: 100, 412), but more comparable at discharge (144 mg/ml, IQR: 69, 275, p = 0.380). Admission myeloperoxidase and calprotectin concentrations were associated with invasive enteropathogens detection (respectively, p = 0.003 and p = 0.002) and lower MUAC (respectively, p = 0.002 and p = 0.012), while admission α-1-antitrypsin was associated with breastfeeding, diarrhea, malaria and pneumonia (all p < 0.05). The only ED biomarker associated with mortality after confounder adjustment was fecal calprotectin (hazard ratio: 1.36, 95% CI:1.07,1.72, p = 0.011) at discharge. Enteric inflammation biomarker concentrations and enteropathogen prevalence were high at hospital admission, but by discharge were lower than among community peers. Interventions to prevent re-colonization with enteropathogens and increased enteric inflammation may improve child health in the post discharge period.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.